Nutriband Inc. NTRB Archives - Page 3 of 6

ThursdayJul 03, 2025 11:15 am

Nutriband Inc. (NASDAQ: NTRB) Added to Four Key Indexes, Rethinking Opioid Safety in a Time of Crisis

Nutriband and Kindeva have completed commercial-scale manufacturing for AVERSA(TM) Fentanyl, a major milestone in the path to FDA approval Updated analyst report raises NTRB’s price target to $15.00 and reiterates an Outperform rating, citing favorable trial pathway and strong execution Aversa abuse-deterrent tech is protected by international patents and may address a global unmet need in safe pain management NTRB boosting their profile and credibility with its recent membership to the Russel Indexes The opioid crisis remains one of the most pressing public health challenges of our time. While synthetic opioids like fentanyl play a crucial role in managing severe…

TuesdayJul 01, 2025 9:40 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Added to Four Russell Indexes in 2025 Reconstitution

Nutriband (NASDAQ: NTRB) has been added to the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes as part of the 2025 Russell indexes reconstitution. CEO Gareth Sheridan called the inclusion a reflection of market recognition and momentum behind the company’s AVERSA pipeline, particularly AVERSA Fentanyl, which has potential peak annual U.S. sales between $80 million and $200 million. Russell indexes, maintained by FTSE Russell, benchmark approximately $10.6 trillion in assets and are widely used by investment managers and institutions. To view the full report, visit https://ibn.fm/Vcsgx About Nutriband Inc. Nutriband is primarily engaged in the development…

MondayJun 23, 2025 9:00 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Price Target Raised to $15 Following AVERSA Fentanyl Manufacturing Milestone

Nutriband (NASDAQ: NTRB) has received a new $15 price target in an updated report from Robert LeBoyer, Senior Vice President and Equity Research Analyst, Biotechnology, at Noble Capital Markets, following the successful completion of commercial manufacturing and scale-up for AVERSA Fentanyl, its abuse-deterrent transdermal patch developed in partnership with Kindeva. The report highlights this milestone as a key inflection point that enables Nutriband to initiate production of clinical supplies and proceed with its planned Investigational New Drug ("IND") application for a Phase 1 trial. The AVERSA program follows the 505(b)(2) regulatory pathway and requires only a single Phase 1 study,…

FridayJun 20, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Reimagining Drug Safety Through Scalable Innovation

Nutriband Inc. has been granted a new U.S. patent for its AVERSA(TM) transdermal abuse-deterrent technology, expanding its domestic IP coverage AVERSA(TM) is designed to prevent misuse, abuse, and accidental exposure of transdermal drugs with abuse potential, such as fentanyl With overdose deaths still plaguing the U.S., Nutriband’s platform has the potential to enhance drug safety across multiple therapeutic categories The opioid crisis remains one of the most persistent public health emergencies in the U.S. While state and federal initiatives have helped curb some of the worst-case trajectories, more than 100,000 Americans still die each year from drug overdoses, a significant…

ThursdayJun 12, 2025 10:30 am

Nutriband Inc. (NASDAQ: NTRB) Reports Double-Digit Revenue Increase, Continued Progress on AVERSA Fentanyl Development

Financial momentum for Nutriband is indicated by its recent Q1 financial report Progress continues development of proprietary AVERSA(TM) Fentanyl, notes quarterly report AVERSA(TM) Fentanyl has the potential to be the world's first abuse-deterrent opioid patch A wave of positive developments continues to build momentum for Nutriband (NASDAQ: NTRB), with recent capital funding, strategic partnerships and an expanded intellectual property portfolio reinforcing its bid to lead in the development of safer transdermal therapies. Nutriband is positioning itself at the forefront of abuse-deterrent drug delivery by advancing its Aversa platforms, notably its flagship fentanyl patch and buprenorphine candidates. Financial momentum for Nutriband…

MondayJun 09, 2025 9:00 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures U.S. Patent for Abuse-Deterrent Transdermal Technology

Nutriband (NASDAQ: NTRB) has been granted U.S. patent No. 12,318,492 for its "Abuse and Misuse Deterrent Transdermal Systems," further strengthening domestic protection for its Aversa(TM) technology. The patent, issued June 3, 2025, enhances the company’s intellectual property portfolio for abuse-deterrent transdermal products designed to curb misuse, diversion, and accidental exposure. Aversa(TM) is currently in development as part of Nutriband’s lead product, Aversa Fentanyl, which aims to be the first abuse-deterrent fentanyl patch on the market, with peak U.S. sales potential projected between $80 million and $200 million. To view the full article, visit https://ibn.fm/BGFEy About Nutriband Inc. Nutriband is primarily…

ThursdayJun 05, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology

Buprenorphine is a medication approved by the U.S. Food and Drug Administration (“FDA”) to treat opioid use disorder and chronic and severe pain Nutriband is developing a novel transdermal delivery system for buprenorphine, projected to reach peak annual sales of $70M - $130M The company’s AVERSA pipeline currently includes two main candidates: AVERSA(TM) Fentanyl and AVERSA(TM) Buprenorphine As the opioid epidemic continues to pose one of the most critical public health crises in the United States and around the world, the need for innovative, safer treatments has never been more urgent. One company, Nutriband (NASDAQ: NTRB), is aiming to transform how opioid-based therapies are administered and protected…

WednesdayJun 04, 2025 10:30 am

Nutriband Inc. (NASDAQ: NTRB): A Relentless Mission Rooted in Purpose, Innovation, and Shareholder Value

NTRB listed on the Nasdaq in 2021, is trading above its IPO price, and hit an all-time high of $11.78 in January of this year Nutriband’s AVERSA abuse-deterrent patch technology is FDA-bound and could command a market potential as high as $800 million annually Serguei Melnik, Founder and President of Nutriband (NASDAQ: NTRB), recently joined The Smart Money Circle Show, where he pulled back the curtain on his no-nonsense approach to biotech entrepreneurship. His grounded tone and unwavering focus on long-term value stand in stark contrast to the conventional biotech playbook. As is typical, the topic of the article focused…

TuesdayJun 03, 2025 9:20 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Noble Capital Markets Emerging Growth Virtual Conference

Nutriband (NASDAQ: NTRB) announced that CEO Gareth Sheridan will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Thursday, June 5 at 4 p.m. ET. The session will feature a fireside-style Q&A open to live audience questions, with 1×1 meetings available for qualified investors. A webcast of the presentation will be accessible post-event on Nutriband’s website and Channelchek.com, where it will remain archived for 90 days. To view the full article, visit https://ibn.fm/WXEv5 About Nutriband Inc. Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse-deterrent fentanyl…

MondayJun 02, 2025 9:20 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Posts Record Q1 Revenue, Advances AVERSA Fentanyl Development

Nutriband (NASDAQ: NTRB) reported first-quarter revenue of $667,000, a 63% year-over-year increase driven by expanded kinesiology tape production through its Pocono Pharma subsidiary and growing retail presence at Target, Walmart, Walgreens, and CVS. The company continues to prioritize shareholder value by scaling Pocono’s output through penetration pricing strategies while advancing development of AVERSA Fentanyl, an abuse-deterrent transdermal opioid patch. A newly formalized partnership with Kindeva Drug Delivery will support shared development costs in exchange for milestone payments as AVERSA moves toward regulatory approval. The product is projected to reach peak U.S. sales of $80 million to $200 million annually. To view…

Site Search

Company Search

Tag: Nutriband Inc. NTRB